Weight loss not working? 3 features can be responsible thewestonforum.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thewestonforum.com Daily Mail and Mail on Sunday newspapers.
The ornithine decarboxylase inhibitor α-difluoromethylornithine, used to treat African sleeping sickness and unwanted hair growth, may also protect β cells of people with new-onset type 1 diabetes.
<p>A new study led by researchers at UChicago Medicine and Indiana University suggests that an existing drug could be repurposed to treat type 1 diabetes, potentially reducing dependence on insulin.</p>
Type 1 diabetes is an autoimmune disease that causes the body's immune system to attack and destroy insulin-producing beta cells in the pancreas. Traditional management of type 1 diabetes has primarily involved replacing the missing insulin with injections which, though effective, can be expensive and burdensome.
The world seems to be entering a new, deadly era of health threats from infectious diseases—old ones we thought we d wiped out, and new ones on the rise